

1 **Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by *ptxP3***
2 **macrolide-resistant *Bordetella pertussis* MT28 clone in China: a genomic**
3 **epidemiology study**

4

5 Pan Fu^{a,b,1}, Gangfen Yan^{c,1}, Yijia Li^a, Li Xie^d, Yuehua Ke^e, Shuxiang Qiu^f, Shuang
6 Wu^f, Xiaolu Shi^f, Jie Qin^a, Jinlan Zhou^c, Guoping Lu^{c*}, Chao Yang^{d*}, Chuanqing
7 Wang^{a,b*}

8

9 ^a Laboratory of Microbiology, Department of Clinical Laboratory, Children's Hospital
10 of Fudan University, National Children's Medical Center, Shanghai, China

11 ^b Nosocomial Infection Control Department, Children's Hospital of Fudan University,
12 National Children's Medical Center, Shanghai, China

13 ^c Pediatric Intensive Care Unit, Children's Hospital of Fudan University, National
14 Children's Medical Center, Shanghai, China

15 ^d The Center for Microbes, Development and Health, CAS Key Laboratory of
16 Molecular Virology and Immunology, Shanghai Institute of Immunity and Infection,
17 Chinese Academy of Sciences, Shanghai, China

18 ^e Department of Bacteriology, Capital Institute of Pediatrics, Beijing, China

19 ^f Shenzhen Center for Disease Control and Prevention, Shenzhen, China

20 ¹ Those authors contribute equally

21

22 *Correspondence

23 Chuanqing Wang, Email: chuanqing523@163.com.

24 Chao Yang, Email: cyang@siii.cas.cn

25 Guoping Lu, Email: lgp@fudan.edu.cn

26

27 **Summary**

28 **Background**

29 The upsurge of pertussis post-COVID-19 and expansion of macrolide-resistant
30 *Bordetella pertussis* (MRBP) pose significant public health challenges worldwide.
31 China has experienced notable pertussis upsurge post-COVID-19, alongside an age
32 shift to older children, vaccine escape and a notable rise in MRBP prevalence. We
33 describe the genomic epidemiological investigation of these events.

34
35 **Method**

36 We did a retrospective, population-based study using culture-positive *B. pertussis*
37 from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital
38 for childhood notifiable infectious diseases, in Shanghai, China between June 2016
39 and March 2024. We analysed strain and pertussis epidemiology dynamics by
40 integrating whole-genome sequencing of 723 strains with antimicrobial susceptibility,
41 transcriptomic profile, and clinical data. We compared the genome sequences of
42 Shanghai strains with 6450 Chinese and global strains.

43
44 **Findings**

45 Coincident with national situation, pertussis cases upsurged post-COVID-19 in
46 Shanghai. At CHFU, the number of confirmed cases (n=349) in the first three months
47 of 2024 exceeded the total case of previously years (n≤177). Post-COVID-19, patients
48 shifted from predominantly infants (90%, 397/442) to widespread infection among
49 older children (infant: 16%, 132/844), with vaccinated individuals surging from 31%
50 (107/340) to 88% (664/756); MRBP prevalence increased from 60% (267/447) to 98%
51 (830/845). The emergence and expansion of a *ptxP3*-lineage, macrolide-resistant novel
52 clone with MLVA type 28, MR-MT28, uniquely capable of causing substantial
53 infections among older children and vaccinated individuals, temporally strongly
54 associated with the pertussis upsurge and epidemiological transition. MR-MT28
55 exhibited increased expression of antigen genes including pertussis toxin genes, along
56 with high incidence of abnormal C-reactive protein, but associated with significantly
57 milder clinical symptoms (e.g. wheezing, facial blushing, $p<0.01$), higher proportion of
58 normal chest computed tomography ($p<0.05$) and lower hospitalization rate ($p<0.01$).
59 Phylogenomic clustering analysis revealed a higher proportion of MR-MT28 strains
60 grouping into clusters representing putative transmission. We reconstructed the
61 evolutionary history of MR-MT28, and showed that it most likely originated in China
62 around 2016 (95% highest probability density: 2013-2017) after acquiring several
63 mutations, including a novel antigen allele *prn150* and 23S rRNA A2047G mutation.
64 Approximately one quarter (26%, 50/195) of MR-MT28 has evolved into predicted
65 PRN-deficient strains. MR-MT28 has been identified in four regions (Anhui,
66 Shanghai, Beijing and Guangdong) of China and continuously detected in Shanghai
67 and Beijing, suggesting domestic spread and colonization.

68
69 **Interpretation**

70 We identified a *ptxP3*-lineage, macrolide-resistant novel clone, MR-MT28, and provide

71 evidence that pathogen evolution is more likely the primary factor driving pertussis
72 upsurge, age shift and vaccine escape. MR-MT28 potentially poses a high global
73 spread risk and warrants global surveillance. Macrolides may no longer be suitable as
74 first-line drugs for pertussis treatment in China.

75

76 **Funding**

77 National Key Research and Development Program of China (2021YFC2701800 and
78 2022YFC2304700), National Natural Science Foundation of China (82202567 and
79 32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences
80 (2022278), Shanghai Rising-Star Program (23QA1410500), and Shanghai municipal
81 three-year action plan for strengthening the construction of the public health system
82 (2023-2025) GWVI-2.1.2.

83

84 **Key words:** pertussis, *Bordetella pertussis*, age shift, vaccine escape,
85 macrolide-resistant, MT28

86

87

88 **Research in context**

89 **Evidence before this study**

90 In the first two months of 2024, an unexpected upsurge in pertussis was seen in both
91 China and Europe. Furthermore, the pertussis upsurge in China exhibited atypical
92 patterns, including an age shift to older children, vaccine escape and a notable
93 increase in macrolide-resistant *Bordetella pertussis* (MRBP) prevalence. We aimed to
94 test the hypothesis linking pertussis upsurge and epidemiological transition to
95 pathogen evolution. We searched PubMed for molecular epidemiology studies of
96 macrolide-resistant *Bordetella pertussis* using the terms ("*Bordetella pertussis*" OR
97 "pertussis" OR "whooping cough") AND ("macrolide resistant" OR "erythromycin
98 resistant") for articles before March 2024 and identified 40 studies. MRBP has been
99 reported in eight countries, including United States, United Kingdom, France, Iran,
100 Cambodia, Vietnam, Japan and China. While MRBP incidence in other countries
101 remained low, it was notably high in China, accounting for 50% and even 90% of
102 strains across various regions. The risk of MRBP spreading out of China was
103 previously considered low, primarily because Chinese strains predominantly belonged
104 to *ptxP1*-lineage, whereas the globally prevalent lineage was *ptxP3*. However, the
105 situation is changing, as *ptxP3*-MRBP strains have been identified in multiple regions
106 of China since 2017. In Shanghai, we identified a sharply increase of *ptxP3*-MRBP
107 prevalence post-COVID-19, coinciding with pertussis age shift to older children and
108 vaccine escape. A similar scenario was independently observed in Beijing.
109 Additionally, there is a significant rise in pertussis cases since the beginning of 2024.
110 Currently, there is a lack of study testing the link between pertussis upsurge,
111 epidemiological transition, and the evolution of its causative pathogen.

112

113 **Added value of this study**

114 Our study identified a *ptxP3*-lineage, macrolide-resistant novel clone, MR-MT28,

115 which is uniquely capable of causing substantial infections among older children and
116 vaccinated population, suggesting enhanced vaccine escape. The emergence and rapid
117 expansion of MR-MT28 temporally strongly associated with the upsurge of pertussis
118 cases, age shift, vaccine escape and notable rise in MRBP prevalence. MR-MT28 was
119 characterized by increased expression of antigen genes long with high incidence of
120 abnormal C-reactive protein, but associated with significantly milder clinical
121 symptoms, which may prolong the interval before seeking medical care, thereby
122 amplifying transmission opportunities. Phylogenomic clustering analysis indicated
123 that MR-MT28 may have increased transmissibility. Therefore, MR-MT28 may have
124 competitive advantages due to antimicrobial resistance, enhanced vaccine escape,
125 increased opportunities for transmission and transmissibility. We reconstructed the
126 evolutionary history of MR-MT28 and showed that it most likely originated in China
127 around 2016 after the acquisition of several mutations, and COVID-19 may have
128 promoted its expansion. Approximately one quarter of MR-MT28 strains has evolved
129 into predicted PRN-deficient strains. Our results showed the domestic spread and
130 colonization of MR-MT28.

131

132 **Implications of all the available evidence**

133 Our study provides evidence that pathogen evolution, rather than the widely accepted
134 notion of waning immunity or ‘immunity debt’, is more likely the primary factor
135 driving pertussis upsurge, age shift and vaccine escape. MR-MT28 potentially poses a
136 high global spread risk, due to its consistent *ptxP3* allele and epidemiology across
137 many counties, together with resistance to first-line drugs and potentially competitive
138 advantages, which warrants global surveillance and research efforts. Macrolides may
139 no longer be suitable as first-line drugs for pertussis treatment in China.

140

141

142 **Introduction**

143 Pertussis (whooping cough) is a highly contagious disease primarily caused by
144 *Bordetella pertussis*. The introduction of the whole-cell vaccines (WCVs) in the
145 1950s, and the switch to acellular vaccines (ACVs) in the 1980–1990s, significantly
146 reduced pertussis disease burden.¹ However, the resurgence of pertussis has been reported
147 globally during the past two decades.^{2–5} The burden of pertussis is still high, with an
148 estimated 24 million cases and 160,700 deaths in children younger than five years in
149 2014.⁶ In China, ACV was applied since 2007 and completely replaced WCV in 2012.
150 Despite over 99% vaccine coverage among children, the numbers of reported
151 pertussis cases sharply increased from <3,000 per year in 2006–2013 to 30,027 in
152 2019.⁷ A reduced incidence of pertussis has been reported in children since the
153 beginning of the COVID-19 pandemic, due to the non-pharmaceutical interventions.^{8,9}
154 However, the recent upsurge in pertussis post-COVID-19 restrictions have been
155 documented in China and Europe.^{10–14} In China, the number of pertussis cases
156 reported in the first two months of 2024 (32,380 cases) was >20 times higher than
157 during the same periods in previous years, approaching the total cases reported for the
158 entire year of 2023 (38,205 cases).^{10,11}

159
160 Pertussis resurgence has been attributed to various factors, including waning immunity,
161 improved diagnostics, and *B. pertussis* evolution.^{2–5} The importance of *B. pertussis*
162 evolution is suggested by the antigenic divergence between circulating strains and
163 vaccine strains. Sequence divergence has been identified in several genes encoding
164 ACV antigens or their promoter, including filamentous hemagglutinin (Fha), pertactin
165 (Prn), fimbriae (Fim), pertussis toxin (Ptx) and its promoter (*ptxP*).¹⁵ *ptxP3* strains are
166 currently dominating infections in most of the high-income countries, probably due to
167 their higher virulence caused by more Ptx production.¹⁶ Moreover, Prn-deficient
168 strains which confer fitness advantages particular to ACV vaccinated populations,
169 have been increasingly reported and became dominant in multiple countries such as
170 United States and Australia.¹⁷ Besides *B. pertussis* evolution toward vaccine escape, the
171 emergence of macrolide-resistant *B. pertussis* (MRBP) mediated by A2047G mutation
172 in the 23s rRNA gene, which confers resistance to first-line drugs such as
173 erythromycin and azithromycin for pertussis treatment, posed further public health
174 issues.¹⁸

175
176 The circulating *B. pertussis* strains and pertussis epidemiology in China differ
177 significantly from those in other countries. *ptxP1* strains have been predominant in
178 China until 2019,^{19–21} rather than globally prevalent *ptxP3* strains. Moreover, the
179 incidence of MRBP in China is notably high, accounting for over 50% and even 90%
180 of strains in various regions,^{21–24} while MRBP remains rare in other countries. Since
181 Chinese MRBP strains were predominantly *ptxP1*, their risk of spreading out of China
182 was previously considered low. Additionally, pertussis patients in China were
183 primarily identified in infants less than one year old,²⁵ unlike the other countries
184 where resurgence of pertussis was more observed in older children and
185 adolescents/adults.^{4,5} However, the situation in China is changing, as *ptxP3*-MRBP

186 strains have been identified in multiple regions of China since 2017.²¹⁻²⁴ In Shanghai,
187 we previously reported that *ptxP3*-MRBP had replaced *ptxP1* strains and dominated
188 infections after 2020, with a substantially increased infections in older, vaccinated
189 children.^{22,23} Similar situation was recently identified in Beijing. During 2021-2022,
190 *ptxP3*-MRBP accounted for 78.8% patients, and the proportion of patients in children
191 over three years old doubled than before.²⁴ The *ptxP3*-MRBP potentially poses a high
192 global spread risk because its consistent *ptxP3* allele and epidemiology across many
193 counties.

194

195 Coincident with national situation, pertussis cases upsurged post-COVID-19 in
196 Shanghai. We have carried out continuous surveillance of *B. pertussis* stains and
197 pertussis in Shanghai since 2016, and obtained strains and corresponding clinical data
198 covering the transition period pre- and post-COVID-19. We previously described the
199 genotype dynamics of *ptxP3*-MRBP based on a subset of strains by multi-locus
200 variable-number tandem-repeat analysis (MLVA)^{22,23} Compared with traditional
201 typing methods such as MLVA, whole-genome sequencing (WGS) provides finer
202 resolution and more comprehensive information including virulence and antimicrobial
203 genes. In this study, we took advantages of WGS and sequenced culture-positive *B.*
204 *pertussis* stains between June 2016 and March 2024. By combining with phenotypic,
205 transcriptomic, and clinical data, we aim to investigate the link between pertussis
206 upsurge, epidemiological transition, and *B. pertussis* evolution. We further compared
207 Shanghai strains with Chinese and global strains to investigate its domestic and global
208 spread risk.

209

210 **Methods**

211 **Isolates sampling and participants**

212 Pertussis is a notifiable disease in China. We did a retrospective, population-based
213 study in Shanghai, the most populous city in China, and enrolled pertussis patients
214 from Children's Hospital of Fudan University (CHFU), the exclusive referral hospital
215 for childhood notifiable infectious diseases. The nasopharyngeal swab samples of
216 patients with suspected pertussis infection are collected and delivered to microbiology
217 laboratory. Pertussis patients were defined as positive culture and/or PCR testing, or
218 showed typical clinical symptoms of pertussis. We studied culture-positive *B.*
219 *pertussis* between June 2016 and March 2024 (all the culture-positive strains between
220 June 2016 and August 2023, and randomly selected strains between September 2023
221 and March 2024, appendix p 2). The laboratory testing results and clinical data were
222 extracted from medical records and all data analysis was anonymous. For comparison,
223 we also included the genomes of 11 randomly selected strains (appendix p 12)
224 collected after 2019 in Beijing (n=8, from Capital Institute of Pediatrics, 2019-2022)
225 and Shenzhen, Guangdong (n=3, from Shenzhen Center for Disease Control and
226 Prevention, 2023). The study protocol was approved by the Ethics Committee of the
227 CHFU (No. 2022-66).

228

229 **Whole-genome sequencing and analysis**

230 Genomic DNA of *B. pertussis* strains were extracted using QIAamp DNA mini kit
231 (QIAGEN) and whole-genome sequencing were performed on Illumina NovaSeq
232 platform. Sequencing data were strictly trimmed and analyzed as previously
233 described.²⁶ Briefly, species identification based on sequencing data were performed
234 using Kraken 2. Core-genome single-nucleotide-polymorphisms (SNPs) were
235 identified using the Snippy pipeline. Maximum-likelihood phylogenetic trees were
236 constructed using RAxML-NG based on core-genome SNPs. Genome assembly was
237 performed using shovill pipeline. Assembled sequences were used for vaccine antigen
238 typing by searching against BIGSdb-Pasteur genomic platform for *Bordetella*.²⁷ Dated
239 phylogeny and population size dynamics were analyzed using BEAST 1.10 with
240 Skygrid coalescent model. We performed pangenome-level analysis to identified
241 lineage/clone-specific genomic variations, including SNPs, gene presence/absence
242 and unitigs using unitig-caller and pyseer. A total of 6439 publicly available genome
243 from 34 countries and six continents were downloaded from NCBI GenBank or SRA
244 database, with accession numbers listed in the appendix (appendix p 13).

245

246 **MLVA and antimicrobial susceptibility testing**

247 Multiple locus variable-number tandem repeat analysis (MLVA) was performed as
248 described by Schouls et al.²⁸ The minimum inhibitory concentrations (MICs) of four
249 antimicrobial agents were determined by the E-test. The standardized interpretation
250 criteria are based on our previous report.²²

251

252 **Transcriptomic analysis and quantification of antigen gene expression**

253 The RNA of *B. pertussis* strains was extracted using QIAGEN RNA extraction kit
254 (TIANGEN BIOTECH, Beijing, China). cDNA library construction and sequencing
255 were performed on Illumina NovaSeq platform at Novogene Co. Ltd. (Beijing, China).
256 Differentially expressed genes identification and pathway enrichment analysis were
257 performed using R packages DESeq2 and ClusterProfiler. Transcriptomic and
258 genomic sequencing data have been deposited in the NCBI Sequence Read Archive
259 (SRA) under accession number PRJNA1071282.

260

261 To quantify antigen gene expression level, reverse transcription was conducted using
262 YEASEN cDNA Synthesis SuperMix for qPCR kit (Yeasen Biotechnology, Shanghai,
263 China). Amplifications of virulence genes were performed using the Applied
264 Biosystems QuantStudio™ 5 Real-Time qPCR system (ThermoFisher SCIENTIFIC,
265 Waltham, MA, US), with initial denaturation for 5 min at 94 °C, and 35 cycles at
266 94 °C for 30 s, annealing for 30 s at 52 °C, followed by elongation at 72 °C for 30 s,
267 and a final step at 72 °C for 5 min. The presence of gene specific amplicons was
268 verified visually by 2% agarose gel electrophoresis using Glodview staining. *B.*
269 *pertussis* ATCC9797 was used as the reference strain and the house-keeping gene *tyrB*
270 was used as the reference gene. The virulence gene expressions were calculated by the
271 comparative CT method ($2^{-\Delta\Delta CT}$).

272

273 **Statistical analysis**

274 Datasets were compared with Chi-squared tests for categorical data and
275 Mann-Whitney test for continuous data using GraphPad Prism 9. *P*-values less than
276 0.05 were considered statistically significant.

277

278 **Role of the funding source**

279 The funding sources for this study had no role in the study design, data collection,
280 data analysis, data interpretation, or writing of the manuscript. The corresponding
281 author had full access to all the data in the study and has final responsibility for the
282 decision to submit this manuscript for publication.

283

284 **Results**

285 Coincident with national situation, pertussis cases upsurged post-COVID-19 in
286 Shanghai (appendix p 1). From June 2016 to March 2024, a total of 2659 patients
287 were diagnosed with pertussis in CHFU. Among these, 1479 (56%) patients were
288 confirmed by positive strain cultures, while the others were diagnosed by positive
289 PCR-detection or showed typical pertussis symptoms. We enrolled all the
290 culture-positive *B. pertussis* strains between June 2016 and August 2023 (n= 714), and
291 100 randomly selected strains (13% culture-positive strains) between September 2023
292 and March 2024. A total of 712 (87%) enrolled culture-positive strains were
293 successfully sequenced and identified as *B. pertussis*. The remaining were identified
294 as other *Bordetella* (n=4) or no longer viable (n=98). Of the 712 patients, 678 (95%)
295 were children patients and the remaining were households. Among children patients
296 with available clinical and vaccination data (table 1), 68% (458/672) were infants
297 (aged ≤1y), 46% (310/674) were female, and 52% (284/546) had been vaccinated. A
298 total of 507 (71%) sequenced strains were MRBP, which are resistant to erythromycin,
299 azithromycin and clarithromycin, but all were susceptible to
300 sulfamethoxazole/trimethoprim. All MRBP strains carried the 23S rRNA A2047G
301 mutation.

302

303 Two phases of pertussis epidemic were identified in Shanghai, with the emergence of
304 COVID-19 as transition point (figure 1). From pre- (n=447) to post-COVID-19
305 (n=845), the proportion of MRBP infections in children increased from 60% to 98%.
306 Moreover, patients shifted from being dominant by infants (90%, 397/442) to
307 widespread infection among older children (infant: 16%, 132/844), with a notable
308 increase in the proportion of vaccinated population, surging from 31% (107/340) to 88%
309 (664/756).

310

311 To characterize the circulating *B. pertussis* lineages, we constructed a phylogenetic tree
312 of 712 Shanghai strains based on core-genome SNPs (figure 2A). Two lineages were
313 identified, which were designated as *ptxP1*- and *ptxP3*-lineage based on *ptxP* alleles.
314 Nearly all (98%, 313/321) *ptxP1*-lineage strains and 50% (194/391) *ptxP3*-lineage
315 strains were MRBP.

316

317 Within *ptxP3*-lineage, all MRBP strains and one MSBP strain clustered together and

318 belonged to a specific clone with MLVA type 28 (MT28), which was designed as
319 MR-MT28. A novel antigen allele *prn150*, with one synonymous mutation (C531T)
320 compared with *prn2*, was identified in MR-MT28. The *prn* of 26% (50/195)
321 MR-MT28 strains were predicted to be PRN-deficient. The genotypes of MR-MT28
322 were *ptxP3/prn150* or PRN-deficient */fhaB1/ptxC2/ptxA1/firm2-1/fim3-1*. Except
323 MR-MT28, all other MT28 strains were MSBP and designated as MS-MT28, which is
324 closely related to MR-MT28 on the phylogenetic tree (figure 2A). Non-MT28 strains of
325 *ptxP3*-lineage was designated as *ptxP3*-other.

326

327 The emergence and expansion of MR-MT28 temporally strongly correlated with the
328 transition of pertussis epidemiology and upsurge of cases (table 1 and figure 2B).
329 Post-COVID-19, MR-MT28 proportion increased sharply and dominated infections
330 since 2022. The proportion of *prn150* or PRN-deficient strains kept increasing
331 alongside the expansion of MR-MT28. Notably, MR-MT28 uniquely caused
332 widespread infection among older children (infant: 25%, 47/189) and accounted for a
333 substantial proportion (87%, 150/172) of infections among vaccinated population. In
334 contrast, other types predominantly infected infants ($\geq 83\%$), with a much lower
335 proportion of infections among vaccinated population ($\leq 39\%$).

336

337 Increased transmission may contribute to the expansion of MR-MT28. To investigate
338 this possibility, genomic clustering analysis based on SNP-distance was performed to
339 infer putative transmissions. Strains from patient-household pairs were most likely
340 from recent transmission. There was no SNP between strains from 30 (90%) of 33
341 patient-household pairs, which were consistent with recent transmission, while the
342 remaining three pairs had 32 or more SNPs. We therefore selected zero SNP
343 difference as the cutoff to infer genomic cluster representing putative transmission. 51%
344 (96/190) MR-MT28 strains were assigned into genomic clusters, which was higher
345 than other types and significantly ($p < 0.01$) higher than *ptxP1* and *ptxP3*-other (figure
346 2C), indicating a potentially increased transmissibility of MR-MT28.

347

348 We randomly selected eight strains (MR-MT28: n=3, MS-MT28: n=3, *ptxP3*-other:
349 n=2) for transcriptomic sequencing to investigate the possible molecular mechanism
350 of MR-MT28 expansion. We found substantial differences of transcriptomic profiles
351 between MT-28 (MR-MT28 and MS-MT28) and *ptxP3*-other strains (figure 3A), with
352 879 differentially expressed genes (DEGs) identified (appendix p 163). Enrichment
353 analysis of DEGs indicated that virulence-related pathways including bacterial
354 secretion system (ko03070) and pertussis (ko05133) were significantly ($p < 0.01$)
355 up-regulated (fold change > 2) and bacterial motility proteins pathway was
356 significantly downregulated (fold change < -2) in MT-28 strains. More specifically,
357 most antigen genes were significantly upregulated, including Ptx encoding genes
358 (*ptxA* to *ptxE*). There was limited difference of transcriptomic profiles between
359 MR-MT28 and MS-MT28, with only eight DEGs not associated with known
360 virulence or antigen genes identified (figure 3B).

361

362 To validate gene expression results, we further quantified the expression of *ptxA* and
363 *prn* of 40 strains (ten randomly selected strains per type) by quantitative PCR (qPCR,
364 figure 3C). Consistent with transcriptomic analysis, the expression levels of *ptxA* in
365 MT28 strains were significantly ($p<0.01$) higher than *ptxP3*-other strains and higher
366 than *ptxP1*-lineage strains ($p=0.06$). There is no significant difference in the
367 expression of *ptxA* and *prn* between MR-MT28 and MS-MT28 under the growth
368 conditions tested, despite MR-MT28 carrying a novel *prn* allele.

369

370 In line with increased expression of Ptx encoding genes, the incidence of abnormal
371 C-reactive protein (CRP) associated with MR-MT28 (20%) was significantly higher
372 than *ptxP1*-lineage (8%) and *ptxP3*-other (9%), and higher than MS-MT28 (5%,
373 $p=0.089$). However, overall, MR-MT28 infection caused milder clinical symptoms
374 (table 1), including spasmodic cough, wheezing, sputum production, facial blushing
375 and post-tussive vomiting, which were significantly ($p<0.01$ or 0.05) milder for
376 MR-MT28 than other types. Moreover, MR-MT28 infections exhibited a significantly
377 ($p<0.05$) higher proportion of normal chest computed tomography results and a
378 significantly ($p<0.01$) lower hospitalization rate. Clinical symptoms among patients
379 with same age category or vaccination status showed similar trends (appendix
380 p1).

381

382 To investigate the origin and spread of MR-MT28 in China and globe, we newly
383 sequenced 11 Beijing and Guangdong strains between 2019 and 2023, and compared
384 with 6439 global strains. Phylogenetic analysis showed that MT28 clone existed in
385 multiple regions worldwide, but so far, MR-MT28 was exclusively identified in China
386 (figure 4A, B).

387

388 The MT28 clone was not a recently emerged one and likely originated from Europe
389 around 2003 (95% highest probability density [HPD]: 1999-2006, figure 3B). It has
390 spread in Europe and United States and was inferred to introduce to China around
391 2007 (95% HPD: 2005-2011). There are only two SNPs between MR-MT28 and
392 MS-MT28 strains: 23S rRNA A2047G mutation and *BP0685* (dehydrogenase/oxidase)
393 G15951A synonymous mutation. The *prn150* was not only identified in MR-MT28,
394 but also found in a MS-MT28 strain closely related to MR-MT28 (figure 2A, 4B).
395 After the acquisition of *prn150*, *BP0685* G15951A mutation and 23S rRNA A2047G
396 mutation, MR-MT28 most likely originated in China in 2016 (95% HPD: 2013-2017),
397 one year prior to the first report of MR-MT28 strain in Anhui, China in 2017.²¹
398 Notably, a sub-clone of MR-MT28 evolved into predicted PRN-deficient around 2019
399 (95% HPD: 2017-2019). Now MR-MT28 has been identified in four regions of China,
400 including Anhui, Shanghai, Beijing and Guangdong (figure 4B). Beyond Shanghai,
401 continuously identification of MR-MT28 occurred in Beijing during 2019-2022,
402 indicating that domestic spread and colonization has occurred.

403

404 The effective population size of MT28 clone has steadily increase since its
405 introduction into China (figure 4C). Intriguingly, following the origination of

406 MR-MT28 in 2016, the overall population size did not increase but instead declined
407 until the advent of COVID-19. Post-COVID-19, MR-MT28 population size increased
408 rapidly, indicating that COVID-19 might be a critical factor for its rapid expansion.

409

410 **Discussion**

411 The continuous surveillance and sampling in Shanghai provide a valuable opportunity
412 to comprehensively investigate the link between pertussis upsurge, epidemiological
413 transition, and *B. pertussis* evolution. Though the integration of large-scale WGS with
414 phenotypic, transcriptomic, and clinical data, we identified and characterized a novel
415 *ptxP3*-lineage, macrolide-resistant clone, MR-MT28, which accounted for a substantial
416 proportion of infections in older children and vaccinated individuals. The emergence
417 and rapid expansion of MR-MT28 temporally strongly associated with pertussis
418 upsurge, age shift, vaccine escape and sharp increase in MRBP prevalence.

419

420 While previous reports have noted pertussis age shift to older children and adolescents
421 and vaccine escape,^{4,5} the situation in Shanghai exhibits distinct features. First, unlike
422 gradual shifts observed in most countries, the shift in Shanghai occurred very quickly.
423 Within two years, the proportion of older children (>1y) and vaccinated individuals
424 surged from 10% and 31% to 84% and 88%, respectively, with the emergence of
425 COVID-19 as the transition point. Second, pertussis shift in other countries was
426 generally associated with the expansion of more virulent *ptxP3* strains, resulting in
427 more severe clinical symptoms and higher hospitalization rates¹⁶. However, although
428 MR-MT28 exhibited increased *ptxA* expression levels and higher incidence of
429 abnormal CRP, it has been associated with generally milder clinical symptoms and a
430 low hospitalization rate. Third, whereas the circulating *ptxP3*-lineage in most
431 countries was polyphyletic with multiple subtypes and no dominant clone reported, a
432 single clone, MR-MT28, dominated infections in Shanghai post-COVID-19 and has
433 spread to multiple regions of China.

434

435 The causes of pertussis upsurge, age shift and vaccine escape have been attributed to
436 multiple factors, including waning immunity, ‘immunity debt’,⁹ improved
437 diagnostics and pathogen evolution, with the first two being considered as the primary
438 factors.²⁻⁵ While waning immunity or ‘immunity debt’ could explain the increased
439 incidence among older children and upsurge of cases, it should not affect *B. pertussis*
440 population composition and dynamics, and cannot explain the observation of
441 MR-MT28 replacing other lineages and dominating infections. Improved diagnostics
442 similarly do not affect *B. pertussis* population dynamics, and our results are based
443 cultured strains, which are independent of diagnostic methods. Moreover, independent
444 observations in Beijing²⁴ provide further evidence that this scenario is not a bias
445 caused by diagnostics.

446

447 We proposed that pathogen evolution is more likely the primary factor driving the
448 scenario in Shanghai and China. MR-MT28 is uniquely capable of causing a
449 substantial proportion of infections among older children and vaccinated individuals,

450 suggesting enhanced vaccine escape. Moreover, the relatively milder clinical
451 symptoms may prolong the interval before seeking medical care, thereby amplifying
452 transmission opportunities. Phylogenomic clustering analysis provided evidence for
453 the increased transmissibility of MR-MT28. Consequently, MR-MT28 may have
454 competitive advantages due to antimicrobial resistance, enhanced vaccine escape,
455 increased opportunities for transmission and transmissibility. In addition, the effective
456 population size of MR-MT28 increased rapidly post-COVID-19, which could be
457 related to the increased family contacts, particularly with unvaccinated infants, the
458 major source for pertussis transmission,²⁹ due to long-term lockdown and home life.
459 These factors combined may have promoted the rapid expansion and dominance of
460 MR-MT28.

461

462 While the molecular mechanism underlying *B. pertussis* vaccine escape remains
463 unclear, three antigen genes have been implicated in this phenomenon:
464 autotransporters genes *brkA* and *vag8*, and surface protein filamentous hemagglutinin
465 gene *fhaB*.³⁰⁻³³ Intriguingly, all three genes were up-regulated in MR-MT28 compared
466 with *ptxP3*-other strains. This, together with upregulation of Ptx encoding genes and
467 other unidentified factors, may contribute to its enhanced vaccine escape. Despite the
468 capacity to infect vaccinated individuals, clinical symptoms of MR-MT28 infection
469 appear to be mild. This suggests that while the vaccine may not entirely prevent
470 infection, it can attenuate clinical symptoms, a phenomenon also observed in other
471 pathogens such as SARS-CoV-2.³⁴

472

473 By integrating public data and 11 newly sequenced genomes from Beijing and
474 Guangdong strains collected after 2019, our results showed the domestic spread and
475 colonization of MR-MT28. Newly sequenced strains were randomly selected, and no
476 information including subtyping and antimicrobial resistance was known in advance.
477 Notably, a surprisingly high proportion of these strains (Beijing: 5/8, Guangdong: 2/3)
478 were MR-MT28, suggesting that MR-MT28 may have cryptically dominated
479 infections in these regions, like in Shanghai, but had not been identified due to limited
480 surveillance and analysis or associated with their milder clinical symptoms. In
481 addition to the expansion in China, MR-MT28 potentially has a high global spread
482 risk because its consistent *ptxP3* allele and epidemiology across many counties. Given
483 its resistance to first-line drugs and potentially competitive advantages, MR-MT28
484 warrants comprehensively global surveillance and research efforts.

485

486 Extremely high prevalence of MRBP indicates that macrolides are no longer suitable
487 as first-line drugs for pertussis treatment in Shanghai and even China.
488 Sulfamethoxazole/trimethoprim could be a good replacement because all MRBP
489 strains were susceptible to it. While traditional drug susceptibility testing relies on
490 strain culture and is time-consuming, PCR testing targeting specific mutations such as
491 23S rRNA A2047G mutation carried by all MRBP strains, offers a supplement or
492 alternative. For MR-MT28, *BP0685* G15951A mutation or *prn150* are candidate
493 targets, though the latter may present some problems (one non-MR-MT28 strains

494 carried *pm150*, 26% MR-MT28 were predicted PRN-deficient).

495

496 Our studies have several limitations. First, most samples used for strain culture were
497 obtained after patients had received antimicrobial treatment, which may introduce bias
498 to the incidence of MRBP. However, this issue is common and remained consistent
499 throughout the sampling period. Second, due to the unavailability of Ptx antibodies in
500 China, we could only investigate the expression levels. Nonetheless, high expression
501 does not necessarily correspond to increased Ptx production and virulence. Finally,
502 while we provided evidence of domestic spread and colonization of MR-MT28, due to
503 the small sample size except Shanghai, the incidence of MR-MT28 in China requires
504 further evaluation based on more samples, especially samples collected
505 post-COVID-19.

506

507 In conclusion, a novel *B. pertussis ptxP3*-lineage clone, MR-MT28, has emerged and
508 dominated infections in Shanghai post-COVID-19. MR-MT28 may have competitive
509 advantages due to antimicrobial resistance, enhanced vaccine escape, increased
510 opportunities for transmission and transmissibility, which drove the pertussis upsurge,
511 age shift, vaccine escape and sharp increase in MRBP prevalence. We reconstructed
512 the evolutionary history of MR-MT28 and demonstrated its domestic spread and
513 colonization. This novel clone potentially has a higher global spread risk because its
514 consistent *ptxP3* allele and epidemiology across many counties, which warrants
515 further comprehensive global surveillance and research efforts. Macrolides may no
516 longer be suitable as first-line drugs for pertussis treatment in China due to the
517 extremely high prevalence of MRBP post-COVID-19.

518

519 **Contributors**

520 CW, PF, CY, and LG contributed to the conception of this project. PF and GY were
521 responsible for collection of clinical and laboratory data. WC and PF performed
522 clinical and laboratory data analysis. CY and LX performed bioinformatics analysis of
523 whole genome sequence data. JQ, JZ and YL participated the genome preparation and
524 qPCR. JQ, YK, SQ, SW, JZ and YL participated in the experiments. CY and PF
525 prepared the manuscript. All authors contributed to the interpretation of results and
526 critical review of the manuscript.

527

528 **Declaration of interests**

529 We declare no competing interests.

530

531 **Acknowledgments**

532 This work was supported by grants from the National Key Research and Development
533 Program of China (2021YFC2701800 and 2022YFC2304700), National Natural
534 Science Foundation of China (82202567 and 32270003), Youth Innovation Promotion
535 Association, Chinese Academy of Sciences (2022278), and Shanghai Rising-Star
536 Program (23QA1410500), and Shanghai municipal three-year action plan for
537 strengthening the construction of the public health system (2023-2025) GWVI-2.1.2.

538 **References**

- 539 1 Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. *Curr Opin Immunol*. 2019;
540 **59**: 72–8.
- 541 2 Mooi FR, Van Der Maas NAT, De Melker HE. Pertussis resurgence: Waning immunity and
542 pathogen adaptation - Two sides of the same coin. *Epidemiol Infect*. 2014; **142**.
- 543 3 Sealey KL, Belcher T, Preston A. Bordetella pertussis epidemiology and evolution in the
544 light of pertussis resurgence. *Infection, Genetics and Evolution*. 2016; **40**: 136–43.
- 545 4 De Cellès MD, Magpantay FMG, King AA, Rohani P. The impact of past vaccination
546 coverage and immunity on pertussis resurgence. *Sci Transl Med* 2018; **10**.
- 547 5 Clark TA. Changing pertussis epidemiology: Everything old is new again. *Journal of*
548 *Infectious Diseases*. 2014; **209**.
- 549 6 Yeung KHT, Duclos P, Nelson EAS, Hutubessy RCW. An update of the global burden of
550 pertussis in children younger than 5 years: a modelling study. *Lancet Infect Dis* 2017; **17**:
551 974–80.
- 552 7 Li L, Deng J, Ma X, *et al*. High prevalence of macrolide-resistant bordetella pertussis and
553 ptxP1 Genotype, Mainland China, 2014-2016. *Emerg Infect Dis*. 2019; **25**.
- 554 8 McIntyre PB, Best E, Byrnes CA, Sinclair O, Trenholme A, Grant CC. Pertussis deaths in
555 New Zealand without community transmission—an infant immunity gap? *Lancet Reg*
556 *Health West Pac*. 2023; **37**.
- 557 9 Cohen R, Ashman M, Taha MK, *et al*. Pediatric Infectious Disease Group (GPIP) position
558 paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the
559 immunity gap? *Infect Dis Now*. 2021; **51**.
- 560 10 Mengyang G, Yahong H, Qinghong M, Wei S, Kaihu Y. Resurgence and atypical patterns
561 of pertussis in China. *Journal of Infection*. 2024; **88**.
- 562 11 Overview of the China national epidemic situation of notifiable infectious diseases in
563 February 2024.
564 https://www.ndcpa.gov.cn/jbkzzx/c100016/second/content/content_176998215784665088
565 0.html.
- 566 12 Reported cases of whooping cough by month in 2023 and 2024 in the Netherlands.
567 [https://www.rivm.nl/en/whooping-cough/current-figures-on-whooping-cough-in-](https://www.rivm.nl/en/whooping-cough/current-figures-on-whooping-cough-in-netherlands)
568 [netherlands](https://www.rivm.nl/en/whooping-cough/current-figures-on-whooping-cough-in-netherlands).
- 569 13 Confirmed cases of pertussis in England by month.
570 [https://www.gov.uk/government/publications/pertussis-epidemiology-in-england-](https://www.gov.uk/government/publications/pertussis-epidemiology-in-england-2024/confirmed-cases-of-pertussis-in-england-by-month)
571 [2024/confirmed-cases-of-pertussis-in-england-by-month](https://www.gov.uk/government/publications/pertussis-epidemiology-in-england-2024/confirmed-cases-of-pertussis-in-england-by-month).
- 572 14 Dalby T. Clarifying pertussis in Denmark. *Lancet Infect Dis*. 2024; **24**.
- 573 15 Bart MJ, Harris SR, Advani A, *et al*. Global population structure and evolution of
574 Bordetella pertussis and their relationship with vaccination. *mBio* 2014; **5**.
- 575 16 Mooi FR, Van Loo IHM, Van Gent M, *et al*. Bordetella pertussis strains with increased
576 toxin production associated with pertussis resurgence. *Emerg Infect Dis* 2009; **15**.
- 577 17 Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-deficient Bordetella pertussis,
578 vaccine-driven evolution, and reemergence of pertussis. *Emerg Infect Dis* 2021; **27**.
- 579 18 Feng Y, Chiu C-H, Heining U, *et al*. Emerging macrolide resistance in Bordetella
580 pertussis in mainland China: Findings and warning from the global pertussis initiative. *The*
581 *Lancet Regional Health-Western Pacific* 2021; **8**: 98.

582 19 Xu Y, Zhang L, Tan Y, Wang L, Zhang S, Wang J. Genetic diversity and population
583 dynamics of *Bordetella pertussis* in China between 1950-2007. *Vaccine* 2015; **33**.

584 20 Yao K, Deng J, Ma X, *et al.* The epidemic of erythromycin-resistant *Bordetella pertussis*
585 with limited genome variation associated with pertussis resurgence in China. *Expert Rev*
586 *Vaccines* 2020; **19**: 1093–9.

587 21 Wu X, Du Q, Li D, *et al.* A Cross-Sectional Study Revealing the Emergence of
588 Erythromycin-Resistant *Bordetella pertussis* Carrying ptxP3 Alleles in China. *Front*
589 *Microbiol* 2022; **13**.

590 22 Fu P, Zhou J, Meng J, *et al.* Emergence and spread of MT28 ptxP3 allele
591 macrolide-resistant *Bordetella pertussis* from 2021 to 2022 in China. *International Journal*
592 *of Infectious Diseases* 2023; **128**: 205–11.

593 23 Fu P, Zhou J, Yang C, *et al.* Molecular Evolution and Increasing Macrolide Resistance of
594 *Bordetella pertussis*, Shanghai, China, 2016–2022. *Emerg Infect Dis* 2024; **30**: 29.

595 24 Hu Y and ZL and SW and MQ and YL and YY and HL and WY and ML and YK.
596 *Bordetella Pertussis* Carrying ptxP3-Allele Spread Rapidly with its Erythromycin
597 Resistance Acquired in China. *SSRN* 2023.

598 25 Ning GJ, GY, WD, LJ, LY, SZ, & YZ. Epidemiology of pertussis in China, 2011–2017.
599 *Chinese Journal of Vaccines and Immunization* 2018; **24**: 264–7.

600 26 Yang C, Li Y, Jiang M, *et al.* Outbreak dynamics of foodborne pathogen *Vibrio*
601 *parahaemolyticus* over a seventeen year period implies hidden reservoirs. *Nat Microbiol*
602 2022; **7**: 1221–9.

603 27 Bridel S, Bouchez V, Brancotte B, *et al.* A comprehensive resource for *Bordetella* genomic
604 epidemiology and biodiversity studies. *Nat Commun* 2022; **13**.

605 28 Schouls LM, Van Der Heide HGJ, Vauterin L, Vauterin P, Mooi FR. Multiple-locus
606 variable-number tandem repeat analysis of Dutch *Bordetella pertussis* strains reveals rapid
607 genetic changes with clonal expansion during the late 1990s. *J Bacteriol* 2004; **186**.

608 29 Wiley KE, Zuo Y, Macartney KK, McIntyre PB. Sources of pertussis infection in young
609 infants: A review of key evidence informing targeting of the cocoon strategy. *Vaccine*.
610 2013; **31**.

611 30 Fernandez RC, Weiss AA. Cloning and sequencing of a *Bordetella pertussis* serum
612 resistance locus. *Infect Immun* 1994; **62**.

613 31 Berggård K, Johnsson E, Mooi FR, Lindahl G. *Bordetella pertussis* binds the human
614 complement regulator C4BP: Role of filamentous hemagglutinin. *Infect Immun* 1997; **65**.

615 32 Marr N, Shah NR, Lee R, Kim EJ, Fernandez RC. *Bordetella pertussis* autotransporter
616 Vag8 binds human C1 esterase inhibitor and confers serum resistance. *PLoS One* 2011; **6**.

617 33 Jongerius I, Schuijt TJ, Mooi FR, Pinelli E. Complement evasion by *Bordetella pertussis*:
618 implications for improving current vaccines. *J Mol Med.* 2015; **93**.

619 34 Haas EJ, Angulo FJ, McLaughlin JM, *et al.* Impact and effectiveness of mRNA BNT162b2
620 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths
621 following a nationwide vaccination campaign in Israel: an observational study using
622 national surveillance data. *The Lancet* 2021; **397**.

623
624
625

Table 1. Demographic, clinical and laboratory characteristics of children patients.

	Total	<i>ptxPI</i>	MR-MT28	MS-MT28	<i>ptxP3</i> -other	<i>p</i> -value (MR-MT28 vs others)
Age						
0-1y	458 (68%)	247 (83%)	47 (25%)	21 (100%)	143 (87%)	All pairs <i>p</i> <0.01
>1-3y	48 (7%)	20 (7%)	16 (8%)	/	12 (7%)	
4-6y	77 (11%)	17 (6%)	56 (30%)	/	4 (2%)	All pairs <i>p</i> <0.01
7-10y	80 (12%)	13 (4%)	61 (32%)	/	6 (4%)	All pairs <i>p</i> <0.01
>10y	9 (1%)	/	9 (5%)	/	/	
Gender						
Female	310 (46%)	136 (45%)	87 (46%)	8 (38%)	79 (48%)	
Male	365 (54%)	163 (55%)	103 (54%)	13 (62%)	86 (52%)	
Vaccination						
Yes	284 (52%)	89 (39%)	150 (87%)	3 (21%)	42 (33%)	All pairs <i>p</i> <0.01
No	262 (48%)	142 (61%)	22 (13%)	11 (79%)	87 (67%)	All pairs <i>p</i> <0.01
Clinical characteristics						
Spasmodic cough	593 (87%)	283 (94%)	136 (72%)	20 (95%)	154 (93%)	All pairs <i>p</i> <0.05
Paroxysmal cough	565 (83%)	252 (83%)	159 (84%)	19 (90%)	135 (82%)	
Cockcrow-like cough	123 (18%)	60 (20%)	29 (15%)	3 (14%)	31 (19%)	
Wheeze	147 (22%)	81 (27%)	14 (7%)	11 (52%)	41 (25%)	All pairs <i>p</i> <0.01
Sputum	446 (66%)	199 (66%)	108 (57%)	20 (95%)	119 (72%)	All pairs <i>p</i> <0.05
Facial blushing	273 (40%)	135 (45%)	33 (17%)	12 (57%)	93 (56%)	All pairs <i>p</i> <0.01
Post-tussive vomiting	202 (30%)	101 (33%)	32 (17%)	8 (38%)	61 (37%)	All pairs <i>p</i> <0.05
Runny nose	251 (37%)	116 (38%)	63 (33%)	10 (48%)	62 (38%)	
Fever history	72 (11%)	38 (13%)	18 (9%)	3 (14%)	13 (8%)	
Apnea	4 (1%)	2 (1%)	1 (1%)	0 (0%)	1 (1%)	
Hospitalization	138 (20%)	81 (27%)	12 (6%)	8 (38%)	37 (22%)	All pairs <i>p</i> <0.01
Hospitalization days	6 (5-10)	6 (5-10)	4 (1-7)	6 (5-10)	7 (5-10)	<i>ptxPI</i> : <i>p</i> <0.01 <i>ptxP3</i> -other: <i>p</i> <0.05
Chest computed tomography (CT)						
Normal	159 (23%)	64 (21%)	59 (31%)	2 (10%)	34 (21%)	All pairs <i>p</i> <0.05
Moderate (bronchitis)	294 (43%)	119 (39%)	90 (47%)	7 (33%)	78 (47%)	
Severe (bronchopneumonia or pneumonia)	225 (33%)	119 (39%)	41 (22%)	12 (57%)	53 (32%)	All pairs <i>p</i> <0.05
Laboratory testing						
Abnormal CRP	78 (12%)	25 (8%)	37 (20%)	1 (5%)	15 (9%)	<i>ptxPI</i> : <i>p</i> <0.01 <i>ptxP3</i> -other: <i>p</i> <0.01
Abnormal WBC	380 (58%)	177 (61%)	86 (47%)	15 (71%)	102 (64%)	All pairs <i>p</i> <0.05

627

Data are n (%) or median (IQR). CRP: C-reactive protein, WBC: white blood cell

628

629



630 **Figure legends**

631 **Figure 1. Pertussis epidemic dynamics in Shanghai, China between 2016 and**
632 **2024.** (A) Monthly number of culture-positive children patients and annually
633 proportions of MRBP/*ptxP3/ptxP3*-MRBP infection, older children (aged >1y) and
634 vaccinated populations. Data from 2020 was not analysed due to insufficient sample
635 size (n=1). (B) Transition of pertussis epidemiology from pre- to post-COVID-19
636 stage.


637
638 **Figure 2. Phylogenomic and epidemiological characteristics of MR-MT28.** (A)
639 Phylogenetic tree, source and antigen gene alleles of Shanghai strains. (B) Temporal
640 dynamics and age and vaccination composition of patients of different lineages/clones.
641 (C) Proportion of genomically clustered strains.

642
643 **Figure 3. Transcriptomic (RNA-seq) and qPCR analyses of gene expression.** (A,B)
644 Volcano plot showing differentially expressed genes (left) and pathways (right). (C)
645 Expression levels of seven antigen genes detected by qPCR. **: $p < 0.01$, NS: not
646 significant.


647
648 **Figure 4. MR-MT28 in China and global context.** (A) Phylogenetic tree of Shanghai
649 and global strains. The colors of outer ring indicated geographical regions. MR-MT28
650 and MS-MT28 were highlighted with red and orange backgrounds. (B) Maximum
651 clade credibility tree of MT28 clone and geographical distribution of MR-MT28 in
652 China. Branch colors indicated geographical regions. Key time points and genetic
653 events were indicated by arrows and triangles. (C) Effective population size dynamics
654 of MT28 clone inferred by Bayesian Skygrid analysis.





A




B



A MR-MT28 & MS-MT28 vs. *ptxP3*-other



B MR-MT28 vs. MS-MT28



C

